Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

Phase 4

Recruiting

• Conditions: Open Angle Glaucoma
• Interventions: Drug: Simbrinza 0.2%-1% Ophthalmic Suspension; Drug: Cosopt PF 2%-0.5% Ophthalmic Solution; Drug: Rocklatan 0.02%-0.005% Ophthalmic Solution; Drug: Latanoprost 0.005% Ophthalmic Solution

• Registration Number: NCT06883123
• Lead Sponsor: Prairie Eye Center

Brief Summary

A randomized, multi-site, parallel-group, prospective study of patients who are adults with a diagnosis of mild to moderate open-angle glaucoma (OAG), currently on an on-label use of combination topical medication of Cosopt and Latanoprost for a minimum of 1 month.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-03-12
• Study First Submitted QC: 2025-03-12
• Study First Posted: 2025-03-19
• Status Verified: 2025-05
• Study Start: 2025-05-14
• Last Update Submitted: 2025-05-14
• Last Update Posted: 2025-05-15
• Primary Completion: 2026-04-01
• Study Completion: 2026-04-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Simbrinza and Rocklatan	Simbrinza 0.2%-1% Ophthalmic Suspension	SIMBRINZA (brinzolamide and brimonidine tartrate) 1%/0.2% ROCKLATAN (netarsudil and latanoprost) 0.02%/0.005%
Simbrinza and Rocklatan	Rocklatan 0.02%-0.005% Ophthalmic Solution	SIMBRINZA (brinzolamide and brimonidine tartrate) 1%/0.2% ROCKLATAN (netarsudil and latanoprost) 0.02%/0.005%
Cosopt and Latanoprost	Cosopt PF 2%-0.5% Ophthalmic Solution	COSOPT (dorzolamide hydrochloride and timolol maleate) 2%/0.5% Latanoprost 0.005%
Cosopt and Latanoprost	Latanoprost 0.005% Ophthalmic Solution	COSOPT (dorzolamide hydrochloride and timolol maleate) 2%/0.5% Latanoprost 0.005%

Primary Outcome Measures

Name	Time	Method
Decrease in mean diurnal IOP	from baseline at week 8	Mean diurnal IOP is determined as the average IOP measured at 8:30am, 12:00pm and 3:30pm

Secondary Outcome Measures

Name	Time	Method
Mean decrease in IOP at 8:30am	from baseline at week 8
Mean decrease in IOP at 12:00pm	from baseline at week 8
Mean decrease in IOP at 4:30pm	from baseline at week 8

Trial Locations

Locations (1)

Prairie Eye Center; 🇺🇸 Springfield, Illinois, United States